Vicki

Interview Transcript "My husband and I really enjoy dancing. We've taken ballroom; we've tried salsa; we've done some swing dancing. So it's just been a nice outlet in our lives.

I was diagnosed in October of 2005. I had an abnormal mammogram.

The stereotactic biopsy originally came back as DCIS, or ductal carcinoma in situ, but when we did the lumpectomy, it turned out to be invasive ductal adenocarcinoma. I was estrogen/progesterone receptor-negative. I was HER2-positive, and I was node-positive.

I started Herceptin® (Trastuzumab) in February of 2006. I was also getting another chemotherapy drug at the time, and I received radiation therapy as well during that time.

We adopted Chloe after my very first chemotherapy treatment. She kept me off the sofa. She was just an inspiration. I had six different wigs, and she knew me in all of them; and she knew me bald. So she was just truly an emotional support system.

I truly feel like the experience is behind me, and I'm back to all my normal routine."

Product Indication: Adjuvant indications
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer:

• As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
• With docetaxel and carboplatin
• As a single agent following multi-modality anthracycline-based therapy

Metastatic indications
Herceptin is indicated:

• In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Important Safety Information: Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please see the Herceptin full prescribing information including Boxed WARNINGS and additional important safety information.

Individual results may vary.